Humira, Advair, Rituxan lead list of best-selling drugs in 2012

03/6/2013 | Genetic Engineering & Biotechnology News

AbbVie's Humira, or adalimumab, topped this list of last year's 20 best-selling drugs based on publicly available figures. GlaxoSmithKline's Advair, or fluticasone and salmeterol, came in second, followed by Roche Holding's Rituxan, or rituximab. Rounding out the top 10 were Sanofi's Lantus, Roche's Herceptin, AstraZeneca's Crestor, Johnson & Johnson's Remicade, Roche's Avastin, Eli Lilly and Co.'s Cymbalta, and Sanofi and Bristol-Myers Squibb's Plavix.

View Full Article in:

Genetic Engineering & Biotechnology News